Paper Details

  1. Home
  2. Paper Details

Pharmacotherapy of Apnea by Cannabimimetic Enhancement, the PACE Clinical Trial: Effects of Dronabinol in Obstructive Sleep Apnea.

Author: AbbottSabra M, AttarianHryar, CarleyDavid W, MalkaniRoneil, PrasadBharati, ReidKathryn J, VernBoris, XieHui, YuanChengbo, ZeePhyllis C

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Overview

A Phase II trial called PACE evaluated dronabinol for obstructive sleep apnea (OSA). Dronabinol is a potential drug treatment for OSA, but currently, there are no approved medications. The study was a blinded, placebo-controlled randomized trial involving individuals with moderate or severe OSA.
Paper Details　
Original Abstract of the Article :
There remains an important and unmet need for fully effective and acceptable treatments in obstructive sleep apnea (OSA). At present, there are no approved drug treatments. Dronabinol has shown promise for OSA pharmacotherapy in a small dose-escalation pilot study. Here, we present initial findings ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5806568/

データ提供：米国国立医学図書館（NLM）

Dronabinol for Obstructive Sleep Apnea: A Promising New Frontier

The [treatment of obstructive sleep apnea (OSA)] remains a significant challenge. While [CPAP] is a well-established therapy, it doesn't work for everyone. This study investigates the potential of [dronabinol], a synthetic cannabinoid, as a novel pharmacotherapy for [OSA].

Dronabinol: A Potential Solution in the Search for Effective OSA Treatment

The researchers conducted a [Phase II clinical trial], [randomly assigning] participants with [moderate or severe OSA] to receive either [dronabinol] or a [placebo]. While the full results are not yet available, this initial report suggests that [dronabinol] may hold promise as a treatment option for [OSA]. However, more research is needed to fully understand its efficacy and safety profile.

Navigating the Desert of Sleep Apnea

Finding effective and well-tolerated treatments for [OSA] is a crucial goal in [sleep medicine]. This study paves the way for exploring the potential of [cannabimimetic drugs] like [dronabinol] in the fight against [OSA]. It's like discovering a hidden spring in the desert of sleep apnea – a potential source of relief for individuals seeking a better night's sleep.

Dr. Camel's Conclusion

Dronabinol, a synthetic cannabinoid, shows early promise as a potential pharmacotherapy for obstructive sleep apnea. More research is needed to confirm its efficacy and safety, but it offers a glimmer of hope for individuals seeking effective OSA treatment. It's like finding a cool breeze in the desert of sleep apnea – a refreshing possibility for those seeking a better night's sleep.

Date :
  1. Date Completed 2019-06-11
  2. Date Revised 2019-06-13
Further Info :

Pubmed ID

29121334

DOI: Digital Object Identifier

PMC5806568

Related Literature

Article Analysis
・Effects of dronabinol
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.